Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 12, 2017, Pages 2046-2054

  Sbidian, E ^a,b,c   Giboin, C ^d   Bachelez, H ^e   Paul, C ^f   Beylot Barry, M ^g   Dupuy, A ^h   Viguier, M ⁱ   Lacour, J P ^j   Schmutz, J L ^k   Bravard, P ^l   Mahe E ^m   Beneton, N ⁿ   Misery, L ^o   Delaporte, E ^p   Modiano, P ^q   Barbarot, S ^r   Regnier, E ^s   Jullien, D ^t   Richard, M A ^u   Joly, P ^v   Tubach, F ^d,w,x   Chosidow, O ^a,b,c   more..

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c Centre d'Investigation Clinique   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e IMAGINE INSTITUTE   (France)

^f University of Toulouse III   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ Centre Hôpitalier Universitaire Robert Debré   (France)

^j CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^k CHU NANCY BRABOIS   (France)

^l LE HAVRE HOSPITAL   (France)

^m CENTRE HOSPITALIER VICTOR DUPOUY   (France)

ⁿ CENTRE HOSPITALIER DU MANS   (France)

^o UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^p LILLE UNIVERSITY HOSPITAL   (France)

^q HÔPITAL SAINT VINCENT DE PAUL   (France)

^r NANTES UNIVERSITY HOSPITAL   (France)

^s ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^t EDOUARD HERRIOT HOSPITAL   (France)

^u TIMONE HOSPITAL   (France)

^v ROUEN UNIVERSITY HOSPITAL   (France)

^w SORBONNE UNIVERSITÉ   (France)

^x Paris Diderot University   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

ADULT; AGE DISTRIBUTION; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRANCE; HEALTH CARE ORGANIZATION; HUMAN; LATENT TUBERCULOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL HISTORY; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PATIENT DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; REGISTER; RISK FACTOR; SCREENING TEST; TREATMENT OUTCOME; CLINICAL DECISION MAKING; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; BIOLOGICAL PRODUCTS; CLINICAL DECISION-MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 85024383794     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14406     Document Type: Article

References (16)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
2. Nast A, Gisondi P, Ormerod AD et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277–2294.
3. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933–943.
4. NICE guidelines. Available from: www.nice.org.uk. Accessed on October 2012.
5. Fenix-Caballero S, Alegre-del Rey EJ, Castano-Lara R, Puigventos-Latorre F, Borrero-Rubio JM, Lopez-Vallejo JF. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013; 38: 286–293.
6. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517–524.
7. Nast A, Sporbeck B, Rosumeck S et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013; 133: 1963–1970.
8. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–1104.
9. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60: 1884–1894.
10. Tsai TF, Chiu HY, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013; 168: 444–446.
11. Tsai TF, Ho V, Song M et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167: 1145–1152.
12. Guinard E, Bulai Livideanu C, Barthelemy H et al. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. J Eur Acad Dermatol Venereol 2016; 30: 1336–1341.
13. Abitbol Y, Laharie D, Cosnes J et al. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns Colitis 2016; 10: 1179–1185.
14. Iskandar IY, Ashcroft DM, Warren RB et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol 2015; 173: 510–518.
15. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091–1096.
16. Cantini F, Niccoli L, Nannini C et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 2016; 45: 519–532.